Skip to content

Serum Progesterone Levels on the Day of Frozen Embryo Transfer (FET) and Pregnancy Outcomes

Serum Progesterone Levels on the Day of Frozen Embryo Transfer (FET) and Pregnancy Outcomes

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04170517
Acronym
ProFET
Enrollment
402
Registered
2019-11-20
Start date
2020-01-02
Completion date
2021-12-31
Last updated
2022-08-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Infertility, Infertility, Female, IVF

Brief summary

Frozen embryo transfer (FET) cycles have become more common in recent years due to a push towards elective single embryo transfer (SET). While it is known that progesterone supplementation during the luteal phase improves clinical pregnancy rates, there is a paucity of prospective data on the impact of serum progesterone levels on pregnancy outcomes in FET cycles. This multicentre prospective cohort study aims to investigate the association between serum progesterone levels on the day of FET and pregnancy outcomes, and to determine a serum progesterone cut-off value above which clinical pregnancy and live birth are more likely to occur. Women undergoing ART-FET cycles at CARE Fertility clinics in the UK will be recruited and their serum progesterone measured on the day of frozen embryo transfer. Follow-up data will be stored in electronic patient records and analysed to determine whether a low serum progesterone level on the day of FET adversely affects ART outcomes.

Interventions

DIAGNOSTIC_TESTMeasurement of serum progesterone on the day of FET

Measurement of serum progesterone on the day of FET

Sponsors

CARE Fertility UK
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
FEMALE
Healthy volunteers
Yes

Inclusion criteria

* All women undergoing ART with FET.

Exclusion criteria

* None. We aim to study the every day patient undergoing FET, and for this we intend to keep the population of the study as unselected as possible.

Design outcomes

Primary

MeasureTime frameDescription
Live birth rate per participant18 monthsBirth of a live fetus at 24 or more weeks of gestational age

Secondary

MeasureTime frameDescription
Miscarriage rate per participant and per pregnancy18 monthsAny clinical pregnancy lost before week 12 of gestation per participant (number of events/number of participants, %)
Implantation rates per participant18 monthsNumber of gestational sacs seen in a 2D transvaginal ultrasound scan divided by the number of embryos transferred per patient (number of events/number of embryos transferred, %)
Biochemical pregnancy rate per participant18 monthsPositive pregnancy test following embryo transfer per participant (number of events/number of participants, %)
Clinical pregnancy rate per participant18 monthsPresence of at least one gestational sac on ultrasound (number of events/number of participants, %)
Ectopic pregnancy rate per participant18 monthsnumber of events/number of participants, %

Countries

United Kingdom

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 12, 2026